ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Lantibiotics are polypeptide antibiotics that feature one or more thioether-linked ring substructures. They form when bacteria modify a precursor polypeptide by dehydrating serine or threonine residues, followed by cyclizing them with a cysteine thiol. This process forms the amino acid lanthionine or methyllanthionine, which makes up one side of the ring (shown). A newly identified lantibiotic, dubbed bicereucin, is unusual in that it features two separate polypeptides that work in tandem to kill bacterial strains such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus, report Liujie Huo and Wilfred A. van der Donk of the University of Illinois, Urbana-Champaign (J. Am. Chem. Soc. 2016, DOI: 10.1021/jacs.6b02513). Working with Bacillus cereus strain SJ1, Huo and van der Donk identified the two bicereucin polypeptides, which they call Bsjα and Bsjβ. Bsjα lacks thioether-connected rings and consequently is not a lantibiotic, whereas Bsjβ is a traditional lantibiotic with one thioether ring. The researchers found that Bsjα appears to bind first to a target on a bacterium surface, and then Bsjβ binds to the bacterium-Bsjα complex. Only when both Bsjα and Bsjβ are present do they have antibiotic activity. The enzymes that process bicereucin may also be useful for producing
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X